If you have been reading about heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
The most-studied of these is the pyruvate dehydrogenase complex. These complexes have three central subunits: E1-3, which are the decarboxylase, lipoyl transferase, and dihydrolipoamide dehydrogenase, respectively. These complexes have a central E2 core and the other subunits surround this core to form the complex. In the gap between these two subunits, the lipoyl domain ferries intermediates between the active sites. The lipoyl domain itself is attached by a flexible linker to the E2 core and the number of lipoyl domains varies from one to three for a given organism. The number of domains has been experimentally varied and seems to have little effect on growth until over nine are added, although more than three decreased activity of the complex. Lipoic acid serves as co-factor to the acetoin dehydrogenase complex catalyzing the conversion of acetoin (3-hydroxy-2-butanone) to acetaldehyde and acetyl coenzyme A. The glycine cleavage system differs from the other complexes, and has a different nomenclature. In this system, the H protein is a free lipoyl domain with additional helices, the L protein is a dihydrolipoamide dehydrogenase, the P protein is the decarboxylase, and the T protein transfers the methylamine from lipoate to tetrahydrofolate (THF) yielding methylene-THF and ammonia. Methylene-THF is then used by serine hydroxymethyltransferase to synthesize serine from glycine. This system is part of plant photorespiration.
BCAAs also inhibit uptake of tyrosine, a precursor of catecholamines such as dopamine and norepinephrine, potentially depressing catecholamine synthesis. Because both serotonin and catecholamines influence exercise capacity, their simultaneous reduction may explain the relatively neutral net effect of BCAA supplementation on performance. BCAA supplementation also alters nitrogen metabolism. During exercise, serum ammonia levels increase, contributing to both muscular and central fatigue. In muscle, high ammonia enhances phosphofructokinase (PFK) activity, further increasing lactic acid production. BCAAs enhance glutamine synthesis, which consumes ammonia and limits its accumulation. Excess ammonia in the brain reduces levels of GABA and glutamate, promoting central fatigue. Finally, BCAA supplementation has been associated with reduced levels of creatine kinase in muscle following exercise, an indicator of reduced muscle damage. Creatine kinase transfers phosphate groups from ATP to form phosphocreatine, which buffers cellular energy supply. Meta-analyses suggest BCAA supplementation may lower creatine kinase levels and attenuate DOMS.
== Further reading == Paradise for Sale: A Parable of Nature. McDaniel and Gowdy. "Christmas Island". Fact sheet 157. National Archives of Australia. 2013. Archived from the original on 4 February 2014. Retrieved 18 January 2014. Weeramantry C. Nauru: environmental damage under international trusteeship. Melbourne: Oxford University Press; 1992. Williams M, Macdonald BK. The phosphateers: a history of the British Phosphate Commissioners and the Christmas Island Phosphate Commission. Carlton, Vic: Melbourne University Press; 1985. Albert Fuller Ellis 1935. Ocean Island and Nauru – their story. Angus and Robertson Limited
A protein subunit is a polypeptide chain or protein molecule that assembles (or "coassembles") with other protein molecules to form a protein complex. Large assemblies of proteins such as viruses often use a small number of types of protein subunits as building blocks. A key step in creating a recombinant protein vaccine is the identification and isolation of a protein subunit from the pathogen which is likely to trigger a strong and effective immune response, without including the parts of the virus or bacterium that enable the pathogen to reproduce. Parts of the protein shell or capsid of a virus are often suitable. The goal is for the protein subunit to prime the immune system response by mimicking the appearance but not the action of the pathogen. Another protein-based approach involves self‐assembly of multiple protein subunits into a virus-like particle (VLP) or nanoparticle. The purpose of increasing the vaccine's surface similarity to a whole virus particle (but not its ability to spread) is to trigger a stronger immune response. Protein subunit vaccines are generally made through protein production, manipulating the gene expression of an organism so that it expresses large amounts of a recombinant gene. A variety of approaches can be used for development depending on the vaccine involved. Yeast, baculovirus, or mammalian cell cultures can be used to produce large amounts of proteins in vitro. Protein-based vaccines are being used for hepatitis B and for human papillomavirus (HPV).
When this happens, the flow of the mobile phase occurs around the stationary phase as well as through it, decreasing resolution. Wall effects have been reduced greatly by advances in column construction. Other advantages of monoliths conferred by their individual construction include greater column to column and batch to batch reproducibility. One technique of creating monolith columns is to polymerize the structure in situ. This involves filling the mold or column tubing with a mixture of monomers, a cross-linking agent, a free-radical initiator, and a porogenic solvent, then initiating the polymerization process under carefully controlled thermal or irradiating conditions. Monolithic in situ polymerization avoids the primary source of column to column variability, which is the packing procedure. Additionally, packed particle columns must be maintained in a solvent environment and cannot be exposed to air during or after the packing procedure. If exposed to air, the pores dry out and no longer provide adequate surface area for reactivity; the column must be repacked or discarded. Further, because particle compression and packing uniformity are not relevant to monoliths, they exhibit greater mechanical robustness; if particulate columns are dropped, for example, the integrity of the column may be corrupted. Monolithic columns are more physically stable than their particulate counterparts.
Sources: en.wikipedia.org
Narrated by Martin Jarvis 7 August Turbo: Qualifying Boost, Paul Ray and electronic engineer Steve Taylor, who designed the engine management unit, at Cosworth; each year in Formula 1, the permitted fuel was reduced - for 1986, it was 195 litres; the EEC-IV electronic fuel injection system, an EPROM design; the Lola THL2 is tested at Boreham Circuit in Essex on 21 February 1986, with Patrick Tambay; Geoff Goddard, of Cosworth, who designed the overall engine; automotive engineer Neil Oatley; aerodynamicist Ross Brawn at Cranfield Institute of Technology; 4 March 1986 at Donington Park in Leicestershire; the Haas Lola team, and Cosworth development engineer Martin Walters; the Lotus 98T, of Team Lotus, with its Renault engine; the wastegate of a turbocharger compressor; the 1986 San Marino Grand Prix in northern Italy on 27 April 1986; the Chernobyl disaster had taken place the day before; Paul Ray notices that the exhaust has cracked near the turbocharger; Narrated by Martin Jarvis, produced by Patrick Uden, made by Uden Associates 14 August Prisoner of Consciousness, Sir Jonathan Miller looked at his research into human memory, and 48-year-old BBC musician Clive Wearing, who could not remember more than 10 seconds; Miller had made The Body in Question for the BBC in 1978, with much of the future Equinox team. Directed by John Dollar, produced by Patrick Uden, and made by Uden Associates 21 August A Short History of the Future: The City.
=== Kinetic isotope effects === Kinetic isotope effect (KIE) occurs in irreversible reactions, such as methanogenesis, and can deviate methane clumped isotopologue composition from its thermodynamic equilibrium. Normally, KIE significantly drives
Norgestrienone, also known as 17α-ethynyl-19-nor-δ9,11-testosterone or as 17α-ethynylestra-4,9,11-trien-17β-ol-3-one, as well as δ9,11-norethisterone or 17α-ethynyltrienolone (17α-ethynyltrenbolone), is a synthetic estrane steroid and a derivative of testosterone and 19-nortestosterone. It is structurally related to the anabolic steroid trenbolone (19-nor-δ9,11-testosterone; the non-17α-ethynylated analogue of norgestrienone), the progestogenic and androgenic steroid gestrinone (the 13β-ethyl variant or 18-methyl derivative of norgestrienone), and the anabolic steroid tetrahydrogestrinone (the 18-methyl and 17α-ethyl variant of norgestrienone).
9 January – Séamus Begley, 73, traditional musician and singer. 16 January Carrie Acheson, 88, politician, TD (1981–1982). Joe Martin, 91, footballer (Dundalk, League of Ireland XI). 18 January – John L. Murray, 79, jurist, chief justice (2004–2011), judge of the Supreme Court (1999–2015) and the ECJ (1992–1999). 19 January Bertie Cunningham, 83, Gaelic footballer (Ballivor, Meath senior team). Peter Thomas, 78, footballer (Waterford, Galway United, national team). Born in England. 20 January – Pierce Higgins, 45, hurler (Tooreen, Ballyhaunis, Mayo senior team), motor neuron disease. 21 January – Micheál Mac Gréil, 91, Jesuit priest, sociologist and writer. 30 January – Eddie Spence, 97, Gaelic footballer (Belfast O'Connell's, Antrim senior team). Born in Northern Ireland. 31 January – Donie Hanlon, 85, Gaelic footballer (Gracefield, Offaly senior team).
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.